Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps

Biotechnology Progress

Volumn 30, Issue 6, 2014, Pages 1341-1347

  Roberts, Peter L ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Gel sanitization; Monoclonal antibody purification; Virus elimination

Indexed keywords

CHLORINE COMPOUNDS; COLUMN CHROMATOGRAPHY; CONTAMINATION; ION EXCHANGE; MONOCLONAL ANTIBODIES; PURIFICATION; SODIUM HYDROXIDE; SURFACE PLASMON RESONANCE;

CHROMATOGRAPHIC COLUMN; GUANIDINIUM CHLORIDES; MONOCLONAL ANTIBODIES (MABS); MONOCLONAL ANTIBODY PURIFICATION; PURIFICATION PROCESS; SANITIZATION; THERAPEUTIC PRODUCTS; VIRUS ELIMINATION;

VIRUSES;

MONOCLONAL ANTIBODY; OCTOXINOL;

CHEMISTRY; ISOLATION AND PURIFICATION; LIQUID CHROMATOGRAPHY; PROCEDURES; ULTRAFILTRATION; VIRUS; VIRUS INACTIVATION;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, LIQUID; OCTOXYNOL; ULTRAFILTRATION; VIRUS INACTIVATION; VIRUSES;

EID: 84914096114     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1984     Document Type: Article

References (35)

1. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, Delward EL. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;84:6033-6040.
2. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA. 1998;279:292-295.
3. TM. Hum Vaccin Immunother. 2013;11:1-11.
4. Centre for Biological Evaluation and Research (CBER), US Food and Drug Administration. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. US Food and Drug Administration; 1997.
5. World Health Organisation (WHO). Requirements for the Use of Animal Cells as Invitro Substrates for the Production of Biologicals. WHO Technical Report Series; 1998;878.
6. International Conference on Harmonisation (ICH). Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. ICH Guideline 1999;Q5A(R1).
7. - volunteers. Blood. 1995;186:1701-1709.
8. st Century. The Netherlands: Kluwer Academic Publishers; 1995:149-153.
9. Baker RM, Brady AM, Combridge BS, Ejim SL, Kingsland SL, Lloyd DA, Roberts PL. Validation of a primary capture process for production of human therapeutic monoclonal antibodies. In: Pyle DL, editor. Seperations for Biotechnology. Royal Society of Chemistry. 1994; 3:53-59.
10. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 848:28-39.
11. Liu H, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. MAbs. 2010;2:480-499.
12. Miesegaes G, Lute S, Brorson K. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng. 2010;106:238-246.
13. Lute S, Norling L, Hanson M, Emery R, Stinson D, Padua K, Blank G, Chen Q, Brorson K. 2008. Robustness of virus removal by protein A chromatography is independent of media lifetime. J Chromatogr A. 2008;1215:17-25.
14. Kemp C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007;35:35-42.
15. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. 2003. Bracketing generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng. 2003;82:321-329.
16. Burnouf T. Chromatograpic removal of viruses from plasma derivatives. Dev Biol Stand. 1993;81:199-209.
17. Strauss DM, Gorrell J, Plancarte M, Blank GS, Chen Q, Yang B. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products. Biotechnol Bioeng. 2009;102:168-175.
18. Miesegaes GR, Lute SC, Read EK, Brorson KA. Viral clearance by flow-through mode ion exchange columns and membrane adsorbers. Biotechnol Prog. 2014;30:124-131.
19. Yang B, Wang H, Ho C, Lester P, Chen Q, Neske F, Baylis SA, Blumel J. Porcine circovirus (PCV) removal by Q sepharose fast flow chromatography. Biotechnol Prog. 2013;29:1464-1471.
20. Roberts PL, Lloyd D. Virus inactivation by protein denaturants used in affinity chromatography. Biologicals. 2007;35:343-347.
21. Cameron R, Davies J, Adcock W, MacGregor A, Barford JP, Cossart Y, Harbour C. The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures. Biologicals. 1997;25:391-401.
22. GE Healthcare. Use of sodium hydroxide for cleaning and sanitising chromatography media and systems. Application Note 18-1124-57, 2009, GE Healthcare Bio-Sciences, Sweden.
23. Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C. Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals. 2003;31:181-185.
24. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion. 1985;25:516-522.
25. Horowitz B, Prince AM, Horowitz MS, Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand. 1993;81:147-161.
26. Roberts PL. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII. Biologicals. 2008;36:330-335.
27. Roberts P. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals. 2000;28:29-32.
28. McCue JT, Selvitelli K, Cecchini D, Brown R. Enveloped virus inactivation using neutral arginine solutions and application in therapeutic protein purification processes. Biotechnol Prog. 2014;30:108-112.
29. Caricati C, Oliveira-Nascimento L, Yoshida J, Caricati A, Raw I, Stephano M. Safety of snake antivenom immunoglobulins. Efficacy of viral inactivation in a complete downstream process. Biotechnol Prog. 2013;29:972-979.
30. Carter J, Lutz H. An overview of viral filtration in biopharmaceutical manufacturing. Eur J Parenter Sci. 2002;7:72-78.
31. Levy R, Phillips MW, Lutz H. 1998. Filtration and the removal of viruses from biopharmaceuticals. In: Meltzer TH, Jornitz MW, editors. Filtration in the Biopharmaceutical Industry. New York: Marcel Dekker; 1998:619-646.
32. Stuckey J, Strauss D, Venkiteshwaran A, Gao J, Luo W, Quertinmont M, O'Donnell S, Chen D. A novel approach to achieving modular retrovirus clearance for a parvovirus filter. Biotechnol Prog. 2014;30:79-84.
33. Roberts P. Application of virus filters to biological products: practical and regulatory considerations. Eur J Parenter Sci. 2000;5:3-9.
34. Willkommen H, Blumel J, Brorson K, Chen D, Chen Q, Groner A, Kreil T, Roberson JS, Ruffing M, Ruiz S. Meeting Report-Workshop on virus removal by filtration: Trends and new developments. PDA J Pharm Sci Technol. 2013;67:98-104.
35. Roberts PL. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors. Biologicals 2014;42:184-190.